Sunovion Pharmaceuticals Inc. (SEPR) Release: Latuda(R) (lurasidone HCl) was Associated with Low Rates of Weight Gain and Metabolic Changes in Patients with Schizophrenia in Data Presented at the 164th Meeting of the American Psychiatric Association
5/18/2011 10:02:42 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a new pooled data analysis on weight and metabolic parameters across short- and long-term studies in adult patients with schizophrenia treated with Latuda® (lurasidone HCl) tablets. These data were presented at the Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii.
comments powered by